Diagnoptics News

What's new?

Read all news items about the AGE Reader and Diagnoptics.

Scientific review emphasises need for AGE measurements and interventions

Groningen, the Netherlands – July 16, 2015

A recent review paper Nenna et al. addresses the important topic of pharmacological approaches against Advanced Glycation End Products (AGEs) in diabetic cardiovascular disease. They conclude the following about measuring AGEs:

“AGE levels add new information for the development and progression of cardiovascular disease in both diabetic and non-diabetic patients, because AGE accumulation occurs before than glycated hemoglobin and more closely correlates with the severity of the disease, predicting the development of cardiovascular complications.”

Diagnoptics (Groningen, the Netherlands) was the first company in the world to introduce a non-invasive technology to assess the level of AGEs in tissue. The AGE Reader, which is currently being used by over 2,500 professionals around the world, provides a measurement result within 12 seconds. This quick and easy measurement offers valuable information about the cardiovascular risk of both diabetic and non-diabetic patients, which then allows for more patient specific therapeutic choices.

The authors also provide an extensive overview of interventions against AGE accumulation. Although these are predominantly tested in preclinical contexts, they appear to show beneficial effects on the development of diabetic complications and cardiovascular diseases. Moreover, two AGE inhibitors are currently being tested in Phase 3 clinical trials.

“Considering the overall results of these studies, anti-AGEs drugs would be an attractive clinical option in the near future.”

This review paper is published in Research in Cardiovascular Medicine. The authors are an international group of scientists from: Rome University of Campus Bio Medico Rome, Cardiac Surgery Centre Cardiologique du Nord de Saint-Denis, Paris and Golden Jubilee National Hospital, Clydebank, Glasgow.

Share this link on:

Latest news items

More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader mu
Non-invasive cardiovascular risk assessment
Age Reader MU
The 'AGE Reader mu' is the next generation AGE Reader that combines a high measurement quality standard with an innovative design, at a reduced pricelevel. The AGE Reader mu is a perfect tool for diabetologists and family doctors. Read more »
Newsletter subscription

If you want to receive the newsletter with information about DiagnOptics' products, please send us your email address.

About the company

More information about Diagnoptics.

Information for patients

Information on Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.